Download PDF
Thromb Haemost 2011; 105(04): 597-604
DOI: 10.1160/TH10-09-0616
Blood Coagulation, Fibrinolysis and Cellular Haemostasis
Schattauer GmbH

Long-term secondary prophylaxis in children, adolescents and young adults with von Willebrand disease

Results of a cohort study
Susan Halimeh
1   Medical Thrombosis and Hemophilia treatment Center Duisburg, Germany
,
Anne Krümpel
2   Pediatric Hematology & Oncology, Univ. Hospital, University of Münster, Germany
,
Hannelore Rott
1   Medical Thrombosis and Hemophilia treatment Center Duisburg, Germany
,
Nadja Bogdanova
3   Institute of Medical Genetics, University of Münster, Germany
,
Ulrich Budde
4   Asklepios laboratory, Hospital Hamburg Altona, Hamburg, Germany
,
Daniela Manner
2   Pediatric Hematology & Oncology, Univ. Hospital, University of Münster, Germany
,
Britta Faeser
1   Medical Thrombosis and Hemophilia treatment Center Duisburg, Germany
,
Rolf Mesters
5   Department of Medicine, Hematology & Oncology, University Hospital, University of Münster, Germany
,
Ulrike Nowak-Göttl   *
2   Pediatric Hematology & Oncology, Univ. Hospital, University of Münster, Germany
› Author Affiliations
Further Information

Publication History

Received: 27 September 2010

Accepted after major revision: 10 February 2010

Publication Date:
28 November 2017 (online)

    Permissions and Reprints

Summary

In patients with von Willebrand disease (VWD) replacement therapy with factor VIII/von Willebrand (VWF) concentrates is increasingly applied as prophylactic regimen. Since 2000, 82 consecutively enrolled patients with clinically relevant bleeding episodes (spontaneous, peri- or postoperative) were diagnosed with VWD [type 1: 42/82; type 2: 24/82; type 3: 13/82; acquired: 3/82]. In all patients, decision for initiating prophylaxis was based on a bleeding score > 2 prior to diagnosis, concomitant with recurrent bleeds associated with anaemia in patients with on-demand VWD therapy. We report results on secondary prophylactic VWF replacement therapy applied in 32 patients [children n=13; adolescents n=7; adults n=12] with VWD [type 1: 4; type 2: 15; type 3: 13], 15 of which were females, and nine of these at the reproductive period. Eight patients were treated with Humate P→ or Wilate→ (n=24). Median [min-max] dose [vWF:RCo] was 40 [20–47] IU/kg, 23 patients were given substitution therapy twice weekly, seven patients three times a week, and two children four times per week. Within a 12-month-period haemoglobin concentrations returned to normal values. Median duration of prophylaxis was three years. Recurrent bleeding episodes stopped in 31 of 32 patients, whereas inhibitors developed in one. Following a 12-month observation period the monthly bleeding frequency and the bleeding score was significantly reduced [3 vs. 0.07; 3 vs. 0: p< 0.001], compared to the preprophylaxis/pre-diagnostic values. The use of secondary prophylactic VWF replacement therapy is an effective tolerated treatment modality, highly beneficial for patients with VWD, who present with recurrent bleeding events during on-demand therapy.

Keywords

von Willebrand Disease - children - young adults - long-term prophylaxis - inhibitor development

* Present address: Head of the Coagulation & Hemostasis Unit, Institute of Clinical Chemistry, University Hospital Kiel & Lübeck, Kiel, Germany.


 

  • References

  • 1 Bolton-Maggs PHB, Lillicrap D, Goudemand J. et val. Von Willebrand disease update: diagnostic and treatment dilemmas. Hemophilia 2008; 14 (Suppl. 03) 56-61.
    PubMedGoogle Scholar
  • 2 Sadler JE. Von Willebrand disease type 1: a diagnosis in search of a disease. Blood 2003; 101: 2089-2093.
    CrossrefPubMedGoogle Scholar
  • 3 Ruggeri ZM, Pareti FI, Mannucci PM. et al. Heightened interaction between platelets and factor VIII/von Willebrand factor in a new subtype of von Willebrand’s disease. N Engl J Med 1980; 302: 1047-1051.
    CrossrefPubMedGoogle Scholar
  • 4 Lak M, Peyvandi F, Mannucci PM. Clinical manifestations and complications of childbirth and replacement therapy in 385 Iranian patients with type 3 von Wille-brand disease. Br J Haematol 2000; 111: 1236-1239.
    CrossrefPubMedGoogle Scholar
  • 5 Federici AB. Prophylaxis of bleeding episodes in patients with von Willebrand’s disease. Blood Transfus 2008; 6 (Suppl. 02) s26-32.
    PubMedGoogle Scholar
  • 6 Makris M. Gastrointestinal bleeding in von Willebrand disease. Thromb Res 2006; 118 (Suppl. 01) S13-S7.
    CrossrefPubMedGoogle Scholar
  • 7 Federici AB, Castaman F, Franchini M. et al. Clinical use of Haemate P in inherited von Willebrand disease: a cohort study on 100 Italian patients. Haematologica 2007; 92: 944-951.
    CrossrefPubMedGoogle Scholar
  • 8 Kadir RA, Chi C. Women and von Willebrand disease. Controversies in diagnosis and management. Sem Thromb Haemost 2006; 32: 605-615.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 9 Berntorp E. Prophylaxis and treatment of bleeding complications in von Wille-brand type 3. Sem Thromb Haemost 2006; 32: 621-625.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 10 Lethagen S. Clinical experience of prophylactic treatment in von Willebrand disease. Thromb Res 2006; 118 (Suppl. 01) S9-S11.
    CrossrefPubMedGoogle Scholar
  • 11 Berntorp E. Prophylaxis in von Willebrand disease. Haemophilia 2008; 14 (Suppl. 05) 47-53.
    CrossrefPubMedGoogle Scholar
  • 12 Abshire T. The role of prophylaxis in the management of von Willebrand disease: today and tomorrow. Thromb Res 2009; 124 (Suppl. 01) 15-19.
    CrossrefPubMedGoogle Scholar
  • 13 Mannucci PM, Franchini M, Castaman G. et al. on behalf of AICE. Evidence-based recommendations on the treatment of von Willebrand disease in Italy. Blood Transfus 2009; 7: 117-126.
    PubMedGoogle Scholar
  • 14 Lillicrap D, Poon MC, Walker I. et al. Efficacy and safety of the factor VIII/von Willebrand factor concentrate Haemate P/Humate P: Ristocetin cofactor unit dosing in patients with von Willebrand disease. Thromb Haemost 2002; 87: 224-230.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 15 Franchini M, Rosetti G, Tagliaferri A. et al. Efficacy and safety of factor VIII/von Willebrand factor concentrate (Haemate P) preventing bleeding during surgery or invasive procedures in patients with von Willebrand disease. Haematologica 2003; 88: 1279-1282.
    PubMedGoogle Scholar
  • 16 Thompson AR, Gill JC, Ewenstein BM. et al. Successful treatment for patients with von Willebrand disease undergoing urgent surgery using factor VIII/von Wille-brand factor concentrate Humate P. Haemophilia 2004; 10: 42-51.
    CrossrefPubMedGoogle Scholar
  • 17 Lethagen S, Kyrle PA, Castaman G. et al. Von Willebrand factor/factor VIII concentrate (Haemate P) dosing based on pharmacokinetics: a prospective multi-center trial in elective surgery. J Thromb Haemost 2007; 5: 1420-1430.
    CrossrefPubMedGoogle Scholar
  • 18 Abshire TC. Prophylaxis and von Willebrand disease. Thromb Res 2006; 118 (Suppl. 01) S3-S7.
    CrossrefPubMedGoogle Scholar
  • 19 Rodeghiero F, Castaman G, Torsetto A. et al. The discriminant power of bleeding history for the diagnosis of type 1 von Willebrand disease: an international multi-center study. J Thromb Haemost 2005; 3: 2619-2626.
    CrossrefPubMedGoogle Scholar
  • 20 Michiels JJ, Berneman Z, Gadisseur A. et al. Classification and characterization of hereditary types 2A, 2B, 2C, 2D, 2E, 2M, 2N, and 2U (unclassifiable) von Wille-brand disease. Clin Applied Thromb Haemost 2006; 12: 397-420.
    PubMedGoogle Scholar
  • 21 Nichols WL, Hultin MB, James AH. et al. Von Willebrand disease (VWD): evidence-based diagnosis and management guidelines, the National Heart, Lung, and Blood Institute (NHLBI) Expert Panel report (USA). Haemophilia 2008; 14: 171-232.
    CrossrefPubMedGoogle Scholar
  • 22 Keeney S, Bowen D, Cumming A. et al. on behalf of the UK hemophilia centre doctors’ organization (UKHCDO). The molecular analysis of von Willebrand disease: A guideline from the UK haemophilia centre doctors’ organization haemophilia genetics laboratory network. Haemophilia 2008; 14: 1099-1111.
    CrossrefPubMedGoogle Scholar
  • 23 Nuss R, Kilcoyne RF, Geraghty S. et al. MRI findings in haemophilic joints treated with radiosynoviorthesis with development of an MRI scale of joint damage. Haemophilia 2000; 6: 162-169.
    CrossrefPubMedGoogle Scholar
  • 24 James AH, Kouides PA, Kadir R. et al. Von Willebrand disease and other bleeding disorders in women: consensus on diagnosis and management from an international expert panel. Am J Obstet Gynecol 2009; 201: 12e1-8.
    CrossrefPubMedGoogle Scholar
  • 25 Federici AB, Gianniello F, Mannucci PM. Secondary long-term prophylaxis in von Willebrand disease: an Italian cohort study. Haematologica reports 2005; 1: 15-20.
    PubMedGoogle Scholar
  • 26 Gouw SC, van der Bom JG, Auerswald G. et al. for the CANAL study group. Recombinant versus plasma-derived factor VIII products and the development of inhibitors in previously untreated patients with severe hemophilia A: the CANAL cohort study. Blood 2007; 109: 4693-4697.
    CrossrefPubMedGoogle Scholar
  • 27 Berntorp E, Abshire T, vWD PN. Steering Committee. The von Willebrand disease prophylaxis network (vWD PN). Thromb Res 2006; 118 (Suppl. 01) S19-S22.
    CrossrefPubMedGoogle Scholar